New hope for kids with rare autoimmune disease: drug trial launches
NCT ID NCT07222553
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests a drug called inebilizumab in 15 children (ages 2 to under 18) with IgG4-related disease, a rare condition where the immune system attacks the body. The main goals are to see how the drug moves through the body, how safe it is, and if it helps control the disease. Participants will be monitored for side effects and flares over 52 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN G4-RELATED DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.